

April 1, 2019 Full Updates for the Alberta Drug Benefit List (ADBL), Alberta Human Services Drug Benefit Supplement (HSDBS) and Palliative Coverage Drug Benefit Supplement (PCDBS)

Please be advised that the annual April 1, 2019 Full Updates to the *Alberta Drug Benefit List (ADBL)*, *Alberta Human Services Drug Benefit List (HSDBS)* and the *Palliative Coverage Drug Benefit Supplement (PCDBS)* have been posted online at www.ab.bluecross.ca/dbl/publications.html

Effective April 1, 2019, the following Drug Products will be removed from the ADBL as the Manufacturer did not submit a Price to the annual Alberta Price Confirmation process:

As per the Alberta Price Policy, Manufacturers with Drug Products currently listed on the ADBL were invited to re-quote the price of their Drug Product(s) for continual listing. Please be advised that the following Drug Products will no longer be listed or eligible for payment under Alberta government-sponsored drug programs effective April 1, 2019 as these Manufacturers have chosen not to re-confirm their price.

All Drug Products scheduled to be removed from the ADBL have been identified as having therapeutic alternatives. *Effective April 1, 2019, the listed products will no longer be a benefit and will not be considered for coverage by Special Authorization. A 30 day transition period will be applied to allow physicians, pharmacists, and patients directly affected by these changes sufficient time to transition to another drug therapy as appropriate and, as of May 1, 2019, claims will no longer pay for these products.*

Patients impacted by the removal of these Drug Products as covered benefits for Alberta government-sponsored drug programs are encouraged to discuss therapeutic alternatives with their health care provider.

DIN/PIN	Product Description
02155966	Cipro 500 mg Tablet
00000981	Mydriacyl 0.5% Ophthalmic Solution
00001007	Mydriacyl 1% Ophthalmic Solution
02229777	Pharixia 0.15 % Rinse
02401967	Tricira Lo 21 Tablet
02401975	Tricira Lo 28 Tablet

Additionally, effective April 1, 2019, the following Drug Products will be removed from the ADBL as these Drug Products have been discontinued by the Manufacturer:

Notification of discontinuation has been received from the manufacturers. The Alberta government-sponsored drug programs previously covered the following Drug Products. Effective April 1, 2019, the listed products will no longer be a benefit and will not be considered for coverage by Special Authorization. A transition period will be applied and, as of May 1, 2019, claims will no longer pay for these products. Patients impacted by the discontinuation of these Drug Products as covered benefits for Alberta government-sponsored drug programs are encouraged to discuss therapeutic alternatives with their health care provider.

... continued from previous page

DIN/PIN	Product Description
02371235	Apo-Losartan/HCTZ 50 mg/12.5 mg Tablet
02371243	Apo-Losartan/HCTZ 100 mg/12.5 mg Tablet
02371251	Apo-Losartan/HCTZ 100 mg/25 mg Tablet
00642223	Apo-Pen-VK 25 mg/ml Oral Liquid
00642231	Apo-Pen-VK 60 mg/ml Oral Liquid
00307246	Blephamide S.O.P. 0.2%/10% Ophthalmic Ointment
01984837	Bonefos 60 mg/ml Injection
02155958	Cipro 250 mg Tablet
02155974	Cipro 750 mg Tablet
02050021	Doxepin 75 mg Capsule
00999918	Ensure Fibre
00803499	Modulon 200 mg Tablet
02396718	Mylan-Fentanyl Matrix 25 mcg/hr Transdermal Patch
02396734	Mylan-Fentanyl Matrix 75 mcg/hr Transdermal Patch
02396742	Mylan-Fentanyl Matrix 100 mcg/hr Transdermal Patch
02230245	pms-Amoxicillin 25 mg/ml Oral Suspension
02230246	pms-Amoxicillin 50 mg/ml Oral Suspension
02230243	pms-Amoxicillin 250 mg Capsule
02418452	pms-Azithromycin 20 mg/ml Oral Suspension
02418460	pms-Azithromycin 40 mg/ml Oral Suspension
00792675	pms-Ferrous Sulfate 30 mg/ml Oral Solution
02238604	pms-Potassium Chloride 1.33 mEq/ml Oral Liquid

For a summary of all updates, please refer to the April 1, 2019 Summary of Changes for highlights of products and pricing changes.

Please note that the online *Interactive Drug Benefit List (iDBL)* is available at www.ab.bluecross.ca/dbl/idbl_main1.html; this is a near real-time application and as such, contains the most up-to-date information.

If this situation continues to be a long-term matter, then these products are subject to the usual review process by the Expert Committee on Drug Evaluation and Therapeutics and must be approved by the Minister of Health for addition to the *ADBL* in order to remain as a benefit.

When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area) • 403-294-4041 (Calgary and area) • 1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area) • FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefits and supplemental claiming information to assist with the submission of your direct bill drug claims. Visit ab.bluecross.ca/providers/pharmacy-home.php



**The Blue Cross symbol and name are registered marks of the Canadian Association of Blue Cross Plans, an association of independent Blue Cross plans. Licensed to ABC Benefits Corporation for use in operating the Alberta Blue Cross Plan. *† Blue Shield is a registered trade-mark of the Blue Cross Blue Shield Association. ABC 82320.794 2019/03

